Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.
This is not a financial advice!
03/22/24
U.S. FDA Approves Broad New Labels for Esperion's NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use
We haven't really seen a big push of the stock price of this news yet.
Recent block buys
Short Float 10.06%
We need to stay in a bullish overal sentiment of the market. If we see a corretion, this play might doesn't work.
We need to break and stay above 2.6-2.7 area before entering a trade.
Keep an eye on 3.0 level, needs to get broken for a further upmove. You can take partial profits at this level if u want to lock in gains.
SL under 1.9
TPs approx. 4.4 or even 5.2
Most info on the chart.
Trade carefully!
Comment
⋅
ANN ARBOR, Mich., April 01, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that Sheldon Koenig, President and CEO, will ring the Nasdaq Stock Market (Nasdaq) opening bell at 9:30 a.m. ET today, April 1, 2024, to commemorate the U.S. Food and Drug Administration's (FDA) recent approval of broad new labels for Esperion's products.
Thanks for the analysis It is going to be a long time down the road for revenues to get a bump out of this. Physician adoption will be slow. I am trading the news and the hype ( and the technicals). I am primary care and emergency doc If it does run get out before the next earnings (IMO). My idea has the same bullish bias. There are so many excellent plays right now it is hard for any stock to get a volume surge. Revenues will not jump until a hard marketing campaign gets underway with medical professionsals and maybe direct to patient on TV.Trader disappointment at earnings will be a playable event on the backside (IMO).
meitshel
⋅
Thank you for your comment, AwesomeAvani. I don't have any medical knowledge. I've been studying trading, with a focus on basic biotech research, for about a year. The biotech sector is quite active right now, and I agree that there are many promising setups and upcoming catalysts in other companies.
AwesomeAvani
⋅
@meitshel, agreed when there are a lot of good setups it makes for a bit of work finding the best which might be intraday pops or long duration trades. My medical knowledge is extreme ( MD/ PhD Biomedical Engineering) = it helps a lot with growth perspective/ market depth and breath et cetera. ESPR could be a huge game changer or flop. It takes a lot of money to market to physicians and other prescribers and hype with TV ads. Their best option is a partnership and co-marketing scheme to take some of the burden away in a quid pro quo for a piece of the profits. Obviously, big pharma names all have an investment in statins and are not candidates. They will try to deep six this. Price needs to undercut generic statins by a significant amount which will impact margins. Without doing that, they cannot get any revenue momentum. One trick ponies have a difficult mountain to climb especially if they do not have proper climbing gear.